Ribociclib succinate

ArtNr	HY-15777B-10mg
Hersteller	MedChem Express
CAS-Nr.	1374639-75-4
Menge	10 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 200 mg 500 mg 50 mg 5 mg
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Brain Cancer Nervous System Cancer
Typ	Inhibitors
Specific against	other
Purity	99.93
Citations	[1]VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21(13):2905-10.\|[2]Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82. Cell Chem Biol. 2018 Feb 15;25(2):135-142.e5.\|Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):4001-4011.\|Biomed Chromatogr. 2020 Mar;34(3):e4783.\|Biomed Pharmacother. 2019 Feb 18;112:108602. \|Biomed Res Int. 2020 Jun 11;2020:9525207.\|bioRxiv. 2024 Nov 15:2024.11.11.623139.\|bioRxiv. 2025 February 23.\|Breast Cancer Res. 2019 Dec 26;21(1):150.\|Cancer Cell. 2024 Aug 27:S1535-6108(24)00305-2.\|Cancer Discov. 2023 Dec 4.\|Cancer Res. 2019 Oct 15;79(20):5245-5259.\|Cancer Res. 2025 Feb 13.\|Cancers (Basel). 2022, 14(22), 5481\|Cancers. 2020 Jun 16;12(6):1596.\|Cell Chem Biol. 2019 Aug 15;26(8):1067-1080.e8. \|Cell Death Dis. 2020 Sep 15;11(9):754.\|Cell Rep Med. 2023 Sep 12;101200.\|Cell Rep Methods. 2023 Oct 23;3(10):100599.\|Cell Rep. 2017 Oct 31;21(5):1386-1398.\|Cell Rep. 2020 Aug 4;32(5):107995.\|Cell. 2023 Jun 8;186(12):2628-2643.e21.\|Clin Cancer Res. 2015 Nov 1;21(21):4947-59.\|Clin Cancer Res. 2024 Dec 30.\|Department of Biochemistry. 2020 Oct.\|Eur J Cancer. 2018 Oct;102:10-22.\|Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.\|Front Oncol. 2022 Apr 8;12:819003.\|Fundam Clin Pharmacol. 2021 Feb 1.\|Harvard Medical School LINCS LIBRARY\|Int J Biol Macromol. 2024 Dec 27:139117.\|Int J Biol Sci. 2019 Jan 1;15(3):522-532. \|J Chromatogr B. 2020 Jun 15;1147:122142.\|J Infect Dis. 2018 Nov 22;218(suppl_5):S365-S387.\|J Pharmaceut Biomed. 2021, 113933.\|J Transl Med. 2022 May 13;20(1):217.\|J Virol. 2023 May 23;e0037023.\|Leuk Res. September 2022, 106920.\|Mil Med Res. 2022 Dec 19;9(1):71.\|Mol Cancer Ther. 2018 May;17(5):897-907.\|Mol Cell. 2017 Oct 19;68(2):336-349.e6.\|Mol Oncol. 2017 Aug;11(8):1035-1049.\|Nat Commun. 2021 Sep 10;12(1):5386.\|Nat Commun. 2022 Aug 10;13(1):4689.\|Nat Commun. 2019 Jun 28;10(1):2860.\|Nature Cancer. 2021 Apr;2(4):429-443.\|Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb 4.\|NPJ Precis Oncol. 2021 Mar 19;5(1):20.\|Patent. US20220354911A1.\|PLoS One. 2022 Dec 22;17(12):e0279522.\|PLoS One. 2024 August 28.\|PLoS One. 2024 Nov 1;19(11):e0308647.\|Research Square Print. November 7th, 2022\|RSC Adv. 2020, 10(38):22668-22683.\|Sci Adv. 2022 Dec 23;8(51):eadc8911.\|Sci Rep. 2021 Mar 8;11(1):5374.\|Sci Rep. 2022 Jul 20;12(1):12420.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Texas Southern University. 2024 July 02.\|Transl Oncol. 2024 Aug 16:49:102092.\|Biochem Pharmacol. 2025 Jan 9:116744.\|bioRxiv. 2023 Sep 16.\|Clin Cancer Res. 2015 Nov 1;21(21):4947-59.\|JCI Insight. 2021 Dec 21;e154402.\|Nat Commun. 2021 Aug 25;12(1):5112.
Smiles	O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(N=C4)=CC=C4N5CCNCC5.OC(CCC(O)=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LEE011 (succinate)
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	CDK
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	552.63
Product Description	Ribociclib succinate (LEE011 succinate) is a highly specific CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1, 000-fold less potent against the cyclin B/CDK1 complex.
Manufacturer - Research Area	Cancer
Solubility	DMSO: 9.38 mg/mL (ultrasonic; warming; heat to 60°C)\|H2O: 4.17 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Cell Cycle/DNA Damage
Isoform	CDK4; CDK6
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-15777B-10mg-safety-datasheet.pdf